Teriparatide Acetate
PTH analog for osteoporosis management. Anabolic bone-building peptide stimulating osteoblast activity, increasing bone mineral density and reducing fracture risk in severe osteoporosis.
Teriparatide is a recombinant human parathyroid hormone (PTH) analog consisting of the biologically active N-terminal portion of PTH (amino acids 1-34). It is the first and only anabolic osteoporosis therapy approved for the treatment of severe osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis. By stimulating osteoblast activity, Teriparatide increases bone mineral density (BMD) and improves bone microarchitecture, reducing the risk of vertebral and non-vertebral fractures.
| Parameter | Specification |
| CAS | 52232-67-4 |
| Molecular Formula | C₁₈₁H₂₉₁N₅₅O₅₁S₂ |
| Molecular Weight | 4117.72 g/mol |
| Category | Bone Health |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Osteoporosis, bone fracture healing, anabolic bone therapy, hypoparathyroidism |
| CAS | 52232-67-4 |
|---|---|
| Applications | Glucocorticoid-induced Osteoporosis, Male Osteoporosis, Severe Osteoporosis (postmenopausal women) |
Related products
-
Ganirelix
CAS: 123246-29-7 -
Orforglipron
CAS: 2212020-52-3Applications: obesity management, Oral GLP-1 Development, Type 2 diabetes -
Aviptadil
CAS: 40077-57-4Applications: Acute respiratory distress syndrome, ARDS, Lung protection, Pulmonary hypertension, VIP analog -
Alarelin
CAS: 79561-22-1Applications: Assisted Reproduction, Endometriosis, Hormone-dependent Tumors, Uterine Fibroids